Vertex Ventures joins $47.6m Series A round in US-based Palleon Pharma

Vertex Ventures
Vertex Ventures. Photographer: Sam Kang Li/Bloomberg

Temasek’s venture capital arm Vertex Ventures has participated in a $47.6 million Series A financing round in Palleon Pharmaceuticals, a US-based biotechnology firm that focuses on developing glycoimmune checkpoint inhibitors to treat cancer.

Continue reading this story with a subscription to DealStreetAsia.